Detalhe da pesquisa
1.
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.
Clin Infect Dis
; 75(5): 786-794, 2022 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34996113
2.
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Liver Int
; 42(6): 1278-1286, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220658
3.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309
4.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
Clin Infect Dis
; 71(5): 1255-1262, 2020 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769793
5.
Glecaprevir/pibrentasvir for 8â¯weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
J Hepatol
; 72(3): 441-449, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682879
6.
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
J Antimicrob Chemother
; 75(3): 648-655, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31873746
7.
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
J Viral Hepat
; 27(5): 497-504, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954087
8.
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Hepatology
; 67(2): 514-523, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28926120
9.
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Hepatology
; 67(4): 1253-1260, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29152781
10.
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Hepatology
; 66(2): 389-397, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28128852
11.
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
J Hepatol
; 67(2): 263-271, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28412293
12.
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Hepatology
; 64(2): 360-9, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26704148
13.
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
J Hepatol
; 63(2): 364-9, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25839406
14.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23830355
15.
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Liver Int
; 34(5): 707-19, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24118703
16.
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
Infect Dis Ther
; 13(4): 891-906, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38570443
17.
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
BMC Infect Dis
; 13: 269, 2013 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23741991
18.
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial.
AIDS Patient Care STDS
; 37(1): 53-59, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626155
19.
Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
Antimicrob Agents Chemother
; 53(10): 4147-52, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19620337
20.
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.
Antimicrob Agents Chemother
; 53(12): 5185-96, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19667283